HS 10398
Alternative Names: HS-10398Latest Information Update: 09 May 2024
At a glance
- Originator Jiangsu Hansoh Pharmaceutical
- Class Urologics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Glomerulonephritis
Most Recent Events
- 02 May 2024 Preclinical trials in Glomerulonephritis in China (PO) (NCT06383897)
- 25 Apr 2024 Jiangsu Hansoh Pharmaceutical plans a phase I trial for Kidney disorder in China (PO, Capsule) in May 2024 (NCT06383897)
- 07 Feb 2024 National Medical Products Administration of the People’s Republic of China issues a clinical trial notice for HS 10398 capsule